Related Experiment Videos
The Sunbelt Melanoma Trial.
1Department of Surgery, University of Louisville, J. Graham Brown Cancer Center, Kentucky 40202, USA. kelly.mcmasters@nortonhealthcare.org
Annals of Surgical Oncology
|October 16, 2001
Summary
This study evaluated lymph node dissection and interferon alfa-2b for early melanoma lymph node metastases. It assessed the effectiveness of these treatments in improving patient outcomes.
Area of Science:
- Oncology
- Dermatology
- Surgical Oncology
Background:
- Melanoma is a serious skin cancer.
- Early lymph node metastasis is a critical prognostic factor.
- Adjuvant therapies are crucial for improving survival rates.
Purpose of the Study:
- To evaluate the role of lymph node dissection in managing early lymph node metastases in melanoma patients.
- To assess the efficacy of adjuvant interferon alfa-2b in this patient group.
- To determine the impact of these interventions on patient outcomes.
Main Methods:
- Prospective randomized trial design.
- Inclusion of patients with early lymph node metastases.
- Comparison of treatment arms with and without lymph node dissection and/or interferon alfa-2b.
Main Results:
- Data on recurrence-free survival and overall survival were collected.
- Toxicity and side effects of interferon alfa-2b were monitored.
- Statistical analysis was performed to determine treatment efficacy.
Conclusions:
- Lymph node dissection plays a significant role in the management of melanoma with lymph node involvement.
- Adjuvant interferon alfa-2b may offer survival benefits for select patients.
- Further research is warranted to optimize treatment strategies for melanoma metastasis.